Member Info for PL75

Can't buy anything on HL

You haven’t seen the director’s cut of the ESMO slides presentation when she called Paul Cuddon a ****.

Seems to be CCs style to update in presentations rather than blow by blow RNSs. I think it's fine.

Great idea on the Q & Q Timster. Let's have 30 mins of us battering them

As always, the more interesting content is likely to come from the Q&A.

Https://youtu.be/TdDHbaYtTKY?si=S-D5wwOU6M89kAAU

That’s not an elephant. They have explained why it’s better, that’s what the pathfinder does. Compare it to the STS market, Doc Tap says it becomes the standard of care overnight. That’s one tiny bit of the potential of the platform. You can’t compare the platform, it’s unique disruptive tech.

Spot on Kevin. Another 'top up' from me. I'm getting like the reverend himself. Last one hasn't worked out so well yet, more powder dry to add again if this nonsense continues.

'despite asking for it twice'. Entitled prick aren't you? Ask DB directly then you bell, it's pretty clear no one on here has the original note, just the link to the article - which you were given but incapable of opening at the time - that's a you problem.

Top bantz innit

Hang on, think I’ve got it…. Anal person’s scribblings here:

https://shorturl.at/TQqyN

I haven't got time to report your posting history.

In fact, just send those ****s a copy of the video presentation and this link for Paul

https://shorturl.at/jS5q5

Watch today’s video, there’s a slide on the population about 5 mins in. As you can see, quite a range of cancer types and previous treatments.

https://x.com/avacta/status/1838567883330253118

No idea about the note, here’s what I found at the time it got mentioned. Why base your note on facts? Just tell them it was peer reviewed.

https://de.investing.com/news/stock-market-news/avacta-enttauscht-bei-phase1studie--deutsche-bank-stuft-aktie-auf-sell-herab-2706637

Thanks for sharing.

Yeah, big reveal of £100s of millions in the bank on the 30th I heard

His previous effort might have been in line. Blatant deliberate misinterpretation is his latest drivel doesn’t seem in line. Especially given the ropey connections they are deeming ok. Their peer review process, probably by his wife, isn’t robust.

Specifically getting it to market on the assumption that it gets AA for their chosen indication. Meanwhile, partners for bigger indications with upfront cash. They've pretty much said they have to continue to aim to get something to market otherwise there's no bluff to have.

Equally likely apparently, but a nicer thread title to have in the meanwhile.

If they fancy going to the fund sharks again, fine, crack on, but make sure there's enough to make it through to ava6k getting to market. Meanwhile, Simon can keep looking for his misplaced inkpot and we can get rid of Dx at the local jumble sale.

Christina Coughlin, MD, PhD, Avacta's CEO, will discuss the results and the Company's operational and clinical progress via the Investor Meet Company platform on 30 September 2024 at 11:00 BST.

So, just the usual. Not a binary presentation that will determine the future of the business. Will it be a deal? Will it be a placing? Or will it just be a results presentation/update. Nothing spectacular has ever been, or ever will be, aligned with a results presentation, other than by chance.

Yes, Steve, it'd be nice to see more detail and I expect we will. From the poster all looked great from a safety perspective, it'd good to know if there are improved efficacy signals from the more frequent dosing. You'd think so, otherwise they've have canned it, why continue if it looks like 3 weekly is optimal.